Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Outpatient Reinfusion of CAR-T Cesnicabtagene Autoleucel (ARI0002h) in Multiple Myeloma Is Feasible and Safe

Beatriz Merchán Muñoz, Alexandra Martínez-Roca, Nuria Ballestar, Cristina Gallego, Nuria Martínez-Cibrián, Valentin Ortiz-Maldonado, Luis Gerardo Rodriguez-Lobato, Nil Albiol, Pilar Ayora, Carla Ramos, Maria Sanchez-Castañon, Manel Juan, Julio Delgado, Jordi Esteve Reyner, Alvaro Urbano-Ispizua, Carlos Fernández de Larrea, Francesc Fernández-Avilés

Blood (2024) 144 (Supplement 1): 7619.

https://doi.org/10.1182/blood-2024-211330

Published: 2024

Journal Articles

Outcomes of Patients with Relapsed Multiple Myeloma Treated with Pomalidomide, Cyclophosphamide, and Dexamethasone Based on Prior Resistance to Anti-CD38 Monoclonal Antibodies

Marta Hidalgo-Soto, Lucía Martín-Rodríguez, Eugenia Abella Montreal, Inmaculada Fernández-Camacho, Mercedes Gironella Mesa, Yolanda González-Montes, M Teresa Cibeira López, Laura Rosinol Dachs, José Miguel Mateos Pérez, Natalia Tovar, Carlos Fernández de Larrea, Luis Gerardo Rodríguez-Lobato

Blood (2024) 144 (Supplement 1): 6955.

https://doi.org/10.1182/blood-2024-200627

Published: 2024

Journal Articles

Enhanced Antitumoral Efficacy of ARI0002h CAR-T with CD28-TMD in Normal and Low BCMA Expressing Myeloma Cells

Luis Gerardo Rodríguez-Lobato, Oriol Cardus, Joan Mañé Pujol, Anthony Battram, David F. Moreno, Lorena Perez-Amill, Beatriz Martín-Antonio, Aina Oliver-Caldés, Anna De Daniel, Natalia Tovar, M Teresa Cibeira López, Laura Rosinol Dachs, Manel Juan, Alvaro Urbano-Ispizua, Carlos Fernández de Larrea

Blood (2024) 144 (Supplement 1): 359.

https://doi.org/10.1182/blood-2024-200123

Published: 2024

Journal Articles

The CAR-Hematotox Identifies Patients at High Risk of Infectious/Inflammatory Complications in a Cohort of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Treated with ARI-0001 (Varnimcabtagene Autoleucel)

Blood (2024) 144 (Supplement 1): 2084.

https://doi.org/10.1182/blood-2024-206082

Published: 2024

Journal Articles

Real-World Treatment Sequencing, Attrition Rates, and Survival Outcomes in Multiple Myeloma: A Retrospective Study over Four Decades

Luis Gerardo Rodríguez-Lobato, Anna De Daniel, Arturo Pereira, Carlos Fernández de Larrea, Natalia Tovar, M Teresa Cibeira López, David F. Moreno, José Miguel Mateos Pérez, Joan Bladé, Laura Rosinol Dachs

Blood (2024) 144 (Supplement 1): 3321.

https://doi.org/10.1182/blood-2024-202549

Published: 2024

Journal Articles

Varnimcabtagene Autoleucel (ARI-0001) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)

Blood (2023) 142 (Supplement 1): 3483.

https://doi.org/10.1182/blood-2023-182896

Published: 2023

Journal Articles

Impact of Salvage and Bridging Therapy in Adult Patients with Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) Referred for Anti-CD19 CAR T-Cell Therapy: An Intention to Treat Analysis

Blood (2023) 142 (Supplement 1): 4875.

https://doi.org/10.1182/blood-2023-187226

Published: 2023

Journal Articles

Genetic Disruption of Blimp-1 Drastically Augments the Persistence and Anti-Tumour Efficacy of BCMA-Targeting CAR-T Cells

Anthony M Battram, Aina Oliver-Caldes, Miquel Bosch i Crespo, Oriol Cardus, David F. Moreno, Luis Gerardo Rodríguez-Lobato, Alvaro Urbano-Ispizua, Carlos Fernandez de Larrea

Blood (2022) 140 (Supplement 1): 2360–2361.

https://doi.org/10.1182/blood-2022-162399

Published: 2022

Journal Articles

Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT

María Queralt Salas, Paola Charry, Nuria Martínez-Cibrian, María Suárez-Lledó, Luis Gerardo Rodríguez-Lobato, Marc Brusosa, María Teresa Solano, Meritxell Nomdedeu, Joan Cid, Miquel Lozano, Jordi Arcarons, Noemí Llobet, Laura Rosinol Dachs, Jordi Esteve, Álvaro Urbano-Ispizua, Enric Carreras, Francesc Fernández-Avilés, Maria Carmen Martinez Munoz, Montserrat Rovira

Blood (2022) 140 (Supplement 1): 4772–4773.

https://doi.org/10.1182/blood-2022-170407

Published: 2022

Journal Articles

Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis

Blood (2022) 140 (Supplement 1): 7616–7618.

https://doi.org/10.1182/blood-2022-167051

Published: 2022

Journal Articles

Evolving Pattern Improves the IMWG 2/20/20 Classification for Patients with Smoldering Multiple Myeloma

Luis Gerardo Rodríguez-Lobato, Anna de Daniel i Bisbe, Natalia Tovar, Raquel Jiménez-Segura, M. Teresa Cibeira, David F. Moreno, Aina Oliver-Caldes, Alexandra Martínez-Roca, Ester Lozano, Joan Bladé Creixenti, Laura Rosinol Dachs, Carlos Fernandez de Larrea

Blood (2022) 140 (Supplement 1): 4341–4342.

https://doi.org/10.1182/blood-2022-165371

Published: 2022

Journal Articles

Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10281–10282.

https://doi.org/10.1182/blood-2022-166764

Published: 2022

Journal Articles

CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell

Blood (2022) 140 (Supplement 1): 10347–10349.

https://doi.org/10.1182/blood-2022-166525

Published: 2022

Journal Articles

Results from a Pilot Study of ARI0002h, an Academic BCMA-Directed CAR-T Cell Therapy with Fractionated Initial Infusion and Booster Dose in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2837.

https://doi.org/10.1182/blood-2021-147188

Published: 2021

Journal Articles

Validation of Different Prognostic Scores in Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era

Blood (2021) 138 (Supplement 1): 3925.

https://doi.org/10.1182/blood-2021-153069

Published: 2021

Journal Articles

Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia

David F. Moreno, Sara Paz, Mari-Pau Mena, Monica Lopez-Guerra, Aina Oliver-Caldes, Anthony M Battram, Luis Gerardo Rodríguez-Lobato, Natalia Tovar, M. Teresa Cibeira, Raquel Jiménez-Segura, Joan Bladé Creixenti, Laura Rosinol, Dolors Colomer, Carlos Fernandez de Larrea

Blood (2021) 138 (Supplement 1): 462.

https://doi.org/10.1182/blood-2021-147168

Published: 2021

Journal Articles

Apheresis Products from Patients with Multiple Myeloma Treated with G-CSF Are a Suitable Source of T Cells for the Production of BCMA-Targeting CAR-T Cells

Anthony M Battram, Aina Oliver-Caldés, Miquel Bosch i Crespo, María Suárez-Lledó, Miquel Lozano, Nuria Martínez-Cibrian, Joan Cid, David F. Moreno, Luis Gerardo Rodríguez-Lobato, Alvaro Urbano-Ispizua, Carlos Fernandez de Larrea

Blood (2021) 138 (Supplement 1): 480.

https://doi.org/10.1182/blood-2021-147774

Published: 2021

Journal Articles

Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Blood (2021) 138 (Supplement 1): 552.

https://doi.org/10.1182/blood-2021-148281

Published: 2021

Journal Articles

Immunoparesis Defined By Heavy/Light Chain Pair Suppression in Smoldering Multiple Myeloma Patients Shows Isotype Specificity

Ignacio Isola, MD, David Moreno, MD, Esther Moga, MD PhD, Mari-Pau Mena, PhD, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, MD PhD, M. Teresa Cibeira, MD PhD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD, Carlos Fernandez de Larrea, MD PhD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-139737

Published: 2020

Journal Articles

ATRA Augments BCMA Expression on Myeloma Cells and Enhances Recognition By BCMA-CAR T-Cells

Estefania Garcia-Guerrero, PhD, Luis Gerardo Rodríguez-Lobato, Sophia Danhof, MD, Belén Sierro-Martínez, Ralph Goetz, Markus Sauer, Jose A. Perez-Simon, MD PhD, Hermann Einsele, MD, Michael Hudecek, MD, Sabrina Prommersbe

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-142572

Published: 2020

NARROW

Outpatient Reinfusion of CAR-T Cesnicabtagene Autoleucel (ARI0002h) in Multiple Myeloma Is Feasible and Safe

Outcomes of Patients with Relapsed Multiple Myeloma Treated with Pomalidomide, Cyclophosphamide, and Dexamethasone Based on Prior Resistance to Anti-CD38 Monoclonal Antibodies

Enhanced Antitumoral Efficacy of ARI0002h CAR-T with CD28-TMD in Normal and Low BCMA Expressing Myeloma Cells

The CAR-Hematotox Identifies Patients at High Risk of Infectious/Inflammatory Complications in a Cohort of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Treated with ARI-0001 (Varnimcabtagene Autoleucel)

Real-World Treatment Sequencing, Attrition Rates, and Survival Outcomes in Multiple Myeloma: A Retrospective Study over Four Decades

Varnimcabtagene Autoleucel (ARI-0001) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)

Impact of Salvage and Bridging Therapy in Adult Patients with Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) Referred for Anti-CD19 CAR T-Cell Therapy: An Intention to Treat Analysis

Genetic Disruption of Blimp-1 Drastically Augments the Persistence and Anti-Tumour Efficacy of BCMA-Targeting CAR-T Cells

Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT

Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis

Evolving Pattern Improves the IMWG 2/20/20 Classification for Patients with Smoldering Multiple Myeloma

Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma

CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell

Results from a Pilot Study of ARI0002h, an Academic BCMA-Directed CAR-T Cell Therapy with Fractionated Initial Infusion and Booster Dose in Patients with Relapsed and/or Refractory Multiple Myeloma

Validation of Different Prognostic Scores in Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era

Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia

Apheresis Products from Patients with Multiple Myeloma Treated with G-CSF Are a Suitable Source of T Cells for the Production of BCMA-Targeting CAR-T Cells

Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Immunoparesis Defined By Heavy/Light Chain Pair Suppression in Smoldering Multiple Myeloma Patients Shows Isotype Specificity

ATRA Augments BCMA Expression on Myeloma Cells and Enhances Recognition By BCMA-CAR T-Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only